JAC Advance Access originally published online on February 27, 2007
Journal of Antimicrobial Chemotherapy 2007 59(4):698-704; doi:10.1093/jac/dkm012
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance
1 Infectious Diseases Department, Hospital Carlos III, Madrid, Spain 2 Centro Sanitario Sandoval, Madrid, Spain 3 Service of Microbiology, Hospital Clinico Universitario, Granada, Spain 4 Service of Microbiology, Hospital Clinico, Valladolid, Spain 5 Fundació IrsiCaixa, Badalona, Spain 6 Service of Microbiology, Hospital Vall d'Hebron, Barcelona, Spain 7 Service of Microbiology, Hospital Xeral Santiago, Spain 8 Service of Microbiology, Hospital General de Asturias, Oviedo, Spain 9 Service of Microbiology, Hospital de la Ribera, Valencia, Spain 10 Internal Medicine Department, Hospital General, Elche, Spain 11 Service of Microbiology, Hospital Marques de Valdecilla, Santander, Spain
Received 23 September 2006; returned 15 November 2006; revised 5 December 2006; accepted 15 January 2007
* Corresponding author. Tel: +34-91-4532500; Fax: +34-91-7336614; E-mail: vsoriano{at}dragonet.es
Background: HIV-1 co-receptor usage may play a critical role in AIDS pathogenesis. Information on viral tropism in HIV-1 seroconverters is scarce, as is the relationship with transmission of drug-resistant viruses.
Methods: All consecutive HIV-1 seroconverters seen between January 1997 and December 2005 in 17 Spanish hospitals were retrospectively analysed. V3 loop amino acid sequences derived from plasma RNA at the time of initial diagnosis were used to predict co-receptor usage. Major drug resistance mutations, plasma HIV RNA, CD4 counts and HIV subtype were considered for subsequent analyses.
Results: A total of 296 HIV-1 seroconverters were identified (84% male; median age 30 years; 61% homosexual men). Median estimated time from infection was 7 months (interquartile range, 3–11). Primary drug resistance mutations were seen in 12.5%, being 9.5% for nucleoside reverse transcriptase inhibitors (NRTI), 4.4% for non-NRTI (NNRTI) and 3% for protease inhibitors (PI). Twenty-four (8.1%) carried non-B subtypes. HIV tropism could be characterized in 203 seroconverters (69%). X4 viruses (either pure or dual/mixed R5/X4) were recognized in 35 (17.2%). There was no association between HIV tropism and mean plasma HIV RNA (4.5 versus 4.4 log copies/mL in R5 versus X4, respectively; P = 0.45) or mean CD4 counts (594 versus 554 cells/mm3, respectively; P = 0.48). The proportion of X4 viruses did not differ in patients infected with wild-type or drug-resistant viruses (17% versus 18%, P = 1). Intravenous drug users tended to show X4 viruses more frequently than individuals infected by sexual relationships (35.7% versus 16.5%, respectively; P = 0.073). After 12 months of follow-up in 78 seroconverters who did not start antiretroviral therapy, more pronounced increases in plasma HIV RNA (+5056 versus –3430) and declines in CD4 cell counts (–126 versus –60) were seen in X4 compared with R5 carriers.
Conclusions: A significant proportion of recent HIV-1 seroconverters harbour X4 viruses (17.2%), without any evidence of association between co-receptor usage, transmission of drug-resistant viruses and HIV subtype.
Keywords: HIV tropism , seroconversion , seroconverters
Members are listed in the Acknowledgement section.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Garrido, V. Roulet, N. Chueca, E. Poveda, A. Aguilera, K. Skrabal, N. Zahonero, S. Carlos, F. Garcia, J. L. Faudon, et al. Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes J. Clin. Microbiol., March 1, 2008; 46(3): 887 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Briz, E. Poveda, M. del Mar Gonzalez, L. Martin-Carbonero, R. Gonzalez-Gonzalez, and V. Soriano Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years J. Antimicrob. Chemother., February 1, 2008; 61(2): 405 - 410. [Abstract] [Full Text] [PDF]
|
|